Eosinophilia-myalgia syndrome case-associated contaminants in commercially available 5-hydroxytryptophan.
Adv Exp Med Biol
; 467: 461-8, 1999.
Article
em En
| MEDLINE
| ID: mdl-10721089
ABSTRACT
Recently, 5-hydroxy-L-tryptophan (5-OHTrp) has been promoted as an alternative to banned L-tryptophan as a dietary supplement. It has been claimed to help alleviate obesity, insomnia, depression, and headaches. However, eosinophilia-myalgia syndrome (EMS)-like symptoms have also been associated with ingestion or exposure to 5-OHTrp. HPLC-UV analysis of EMS-implicated 5-OHTrp revealed the presence of peak X, described as case-implicated. We show that peak X is actually a family of contaminants with the same molecular weight (234 Da) and similar HPLC retention times. We also demonstrate that all eight samples of commercially available 5-OHTrp analyzed by HPLC-MS contained three or more contaminants of the peak X family. The significance of these findings is discussed.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
5-Hidroxitriptofano
/
Contaminação de Medicamentos
/
Síndrome de Eosinofilia-Mialgia
Tipo de estudo:
Risk_factors_studies
Idioma:
En
Revista:
Adv Exp Med Biol
Ano de publicação:
1999
Tipo de documento:
Article
País de afiliação:
Estados Unidos